{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T11:28:48Z","timestamp":1786447728725,"version":"build-2736575974"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100014584","name":"Universit\u00e4tsmedizin der Johannes Gutenberg-Universit\u00e4t Mainz","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014584","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Brexucabtagene-autoleucel (brexu-cel) is an anti-CD19 chimeric antigen receptor T-cell (CAR-T) product approved for relapsed\/refractory Mantle Cell Lymphoma (MCL) after two prior treatment lines, including Bruton tyrosine kinase inhibitors (BTKi). Patients with high-risk (hr) disease\u2014defined by high-intermediate or high-risk MIPI-c, p53 overexpression, or TP53 alterations\u2014have a poor prognosis, underscoring the need for improved first-line strategies. The European Mantle Cell Lymphoma Network therefore designed a phase II trial to investigate the incorporation of brexu-cel into first-line therapy for hr MCL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>CARMAN is a randomized controlled, international, multicenter, open-label phase II trial evaluating efficacy, safety, and tolerability of an abbreviated induction followed by first-line brexu-cel and 6 months Ibrutinib maintenance (Arm A) as compared to standard of care induction and maintenance (Arm B). In Arm A, induction consists of two cycles of ibrutinib plus rituximab (I\u2009+\u2009R) followed by two cycles of R-CHOP plus ibrutinib (I). R-CHOP\u2009+\u2009I may be omitted in patients achieving complete or partial remission after two cycles of I\u2009+\u2009R, who then receive one additional I\u2009+\u2009R cycle before brexu-cel infusion and I maintenance. Arm B comprises a TRIANGLE-like regimen based on age, fitness, and investigator choice (alternating R-CHOP plus ibrutinib\/R-DHAP or IR-bendamustine), followed by IR maintenance. Overall, 150 patients from five European countries are randomized 1:1. The primary endpoint is failure-free survival from randomization, with failure event defined as the earliest of stable disease at the end of induction (Arm B, or Arm A if brexu-cel is not infused) or within 12 weeks from CAR-T-cell infusion (Arm A), disease progression after induction, or death from any cause. Secondary endpoints include efficacy (overall and complete response rates and PET-negative CR rate 6 months from randomization as assessed according to Lugano criteria, molecular remission rate as measured by MRD), safety and tolerability (adverse events graded according to CTCAE), and patient-reported quality of life as measured by the EORTC-QLQ-C30 and EORTC-QLQ-NHL-HG29 questionnaires.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>When complete, CARMAN will provide important information on efficacy and safety in first-line CAR-T cell therapy in hr MCL and has the potential to prepare a practice changing confirmatory trial for these difficult-to-treat patients. Recruitment is ongoing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>EU clinical trial number: 2022-502405-15-00.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-16602-1","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T10:23:32Z","timestamp":1786443812000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Trials in progress: CARMAN \u2013 study protocol of a randomized controlled, international, multicenter, open-label phase II trial evaluating early treatment intensification in patients with high-risk mantle cell lymphoma using CAR-T-cell treatment after an abbreviated induction therapy with rituximab and ibrutinib and 6 months ibrutinib maintenance as compared to standard of care induction and maintenance"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2395-052X","authenticated-orcid":false,"given":"Marie-Kristin","family":"Tilch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Trneny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Gin\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Hermine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke","family":"Ohler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Herold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Hoster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linmiao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Pott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Dreyling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Hess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"issue":"19","key":"16602_CR1","doi-asserted-by":"publisher","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","volume":"116","author":"M Sant","year":"2010","unstructured":"Sant M, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;116(19):3724\u201334.","journal-title":"Blood"},{"issue":"11","key":"16602_CR2","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1038\/bjc.2011.450","volume":"105","author":"A Smith","year":"2011","unstructured":"Smith A, et al. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer. 2011;105(11):1684\u201392.","journal-title":"Br J Cancer"},{"issue":"68","key":"16602_CR3","doi-asserted-by":"publisher","first-page":"112516","DOI":"10.18632\/oncotarget.22367","volume":"8","author":"S Fu","year":"2017","unstructured":"Fu S, et al. Trends and variations in mantle cell lymphoma incidence from 1995 to 2013: A comparative study between Texas and National SEER areas. Oncotarget. 2017;8(68):112516\u201329.","journal-title":"Oncotarget"},{"issue":"36","key":"16602_CR4","doi-asserted-by":"publisher","first-page":"4302","DOI":"10.1200\/JCO.20.02287","volume":"38","author":"P Jain","year":"2020","unstructured":"Jain P, et al. High-Risk Mantle Cell Lymphoma: Definition, Current Challenges, and Management. J Clin Oncol. 2020;38(36):4302\u201316.","journal-title":"J Clin Oncol"},{"issue":"2","key":"16602_CR5","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/modpathol.2017.135","volume":"31","author":"Z Hu","year":"2018","unstructured":"Hu Z, et al. CD200 expression in mantle cell lymphoma identifies a unique subgroup of patients with frequent IGHV mutations, absence of SOX11 expression, and an indolent clinical course. Mod Pathol. 2018;31(2):327\u201336.","journal-title":"Mod Pathol"},{"issue":"20","key":"16602_CR6","doi-asserted-by":"publisher","first-page":"5307","DOI":"10.1158\/0008-5472.CAN-12-1615","volume":"72","author":"A Navarro","year":"2012","unstructured":"Navarro A, et al. Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. Cancer Res. 2012;72(20):5307\u201316.","journal-title":"Cancer Res"},{"issue":"1","key":"16602_CR7","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s13046-017-0652-8","volume":"36","author":"H Ye","year":"2017","unstructured":"Ye H, et al. Smoldering mantle cell lymphoma. J Exp Clin Cancer Res. 2017;36(1):185.","journal-title":"J Exp Clin Cancer Res"},{"issue":"13","key":"16602_CR8","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1182\/bloodadvances.2019001350","volume":"4","author":"HA Hill","year":"2020","unstructured":"Hill HA, et al. Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis. Blood Adv. 2020;4(13):2927\u201338.","journal-title":"Blood Adv"},{"issue":"2","key":"16602_CR9","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","volume":"111","author":"E Hoster","year":"2008","unstructured":"Hoster E, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111(2):558\u201365.","journal-title":"Blood"},{"issue":"13","key":"16602_CR10","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1200\/JCO.2013.52.2466","volume":"32","author":"E Hoster","year":"2014","unstructured":"Hoster E, et al. Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network. J Clin Oncol. 2014;32(13):1338\u201346.","journal-title":"J Clin Oncol"},{"issue":"9","key":"16602_CR11","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1038\/s41375-023-01977-y","volume":"37","author":"G Scheubeck","year":"2023","unstructured":"Scheubeck G, et al. Clinical outcome of Mantle Cell Lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression). Leukemia. 2023;37(9):1887\u201394.","journal-title":"Leukemia"},{"issue":"2","key":"16602_CR12","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/bjh.15170","volume":"181","author":"A Smith","year":"2018","unstructured":"Smith A, et al. Impact of novel therapies for mantle cell lymphoma in the real world setting: a report from the UK\u2019s Haematological Malignancy Research Network (HMRN). Br J Haematol. 2018;181(2):215\u201328.","journal-title":"Br J Haematol"},{"issue":"9","key":"16602_CR13","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1038\/bjc.2015.94","volume":"112","author":"A Smith","year":"2015","unstructured":"Smith A, et al. Lymphoma incidence, survival and prevalence 2004\u20132014: sub-type analyses from the UK\u2019s Haematological Malignancy Research Network. Br J Cancer. 2015;112(9):1575\u201384.","journal-title":"Br J Cancer"},{"issue":"10044","key":"16602_CR14","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","volume":"388","author":"O Hermine","year":"2016","unstructured":"Hermine O, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet. 2016;388(10044):565\u201375.","journal-title":"Lancet"},{"issue":"Supplement 2","key":"16602_CR15","doi-asserted-by":"publisher","first-page":"pLBA","DOI":"10.1182\/blood-2024-212973","volume":"144","author":"TS Fenske","year":"2024","unstructured":"Fenske TS, et al. Lack of Benefit of Autologous Hematopoietic Cell Transplantation (auto-HCT) in Mantle Cell Lymphoma (MCL) Patients (pts) in First Complete Remission (CR) with Undetectable Minimal Residual Disease (uMRD): Initial Report from the ECOG-ACRIN EA4151 Phase 3 Randomized Trial. Blood. 2024;144(Supplement 2):pLBA\u20136.","journal-title":"Blood"},{"issue":"10441","key":"16602_CR16","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1016\/S0140-6736(24)00184-3","volume":"403","author":"M Dreyling","year":"2024","unstructured":"Dreyling M, et al. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network. Lancet. 2024;403(10441):2293\u2013306.","journal-title":"Lancet"},{"issue":"10542","key":"16602_CR17","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1016\/S0140-6736(26)00362-4","volume":"407","author":"M Dreyling","year":"2026","unstructured":"Dreyling M, et al. Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18\u201365 years with mantle cell lymphoma (TRIANGLE):4\u00b75-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network. Lancet. 2026;407(10542):1953\u201367.","journal-title":"Lancet"},{"issue":"3","key":"16602_CR18","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1200\/JCO.19.01294","volume":"38","author":"HC Kluin-Nelemans","year":"2020","unstructured":"Kluin-Nelemans HC, et al. Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial. J Clin Oncol. 2020;38(3):248\u201356.","journal-title":"J Clin Oncol"},{"issue":"7","key":"16602_CR19","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1200\/JCO.23.01586","volume":"42","author":"C Sarkozy","year":"2024","unstructured":"Sarkozy C, et al. Long-Term Follow-Up of Rituximab Maintenance in Young Patients With Mantle-Cell Lymphoma Included in the LYMA Trial: A LYSA Study. J Clin Oncol. 2024;42(7):769\u201373.","journal-title":"J Clin Oncol"},{"issue":"17","key":"16602_CR20","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","volume":"130","author":"CW Eskelund","year":"2017","unstructured":"Eskelund CW, et al. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood. 2017;130(17):1903\u201310.","journal-title":"Blood"},{"issue":"26","key":"16602_CR21","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1056\/NEJMoa2201817","volume":"386","author":"L Wang Michael","year":"2022","unstructured":"Wang Michael L, et al. Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma. N Engl J Med. 2022;386(26):2482\u201394.","journal-title":"N Engl J Med"},{"key":"16602_CR22","unstructured":"Wang M, et al. Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma. J Clin Oncol. 0(0):JCO-25-00690."},{"issue":"2","key":"16602_CR23","doi-asserted-by":"publisher","first-page":"e68","DOI":"10.3324\/haematol.2018.198812","volume":"104","author":"TA Eyre","year":"2019","unstructured":"Eyre TA, et al. Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy. Haematologica. 2019;104(2):e68\u201371.","journal-title":"Haematologica"},{"issue":"12","key":"16602_CR24","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1182\/blood-2015-10-673145","volume":"127","author":"P Martin","year":"2016","unstructured":"Martin P, et al. Postibrutinib outcomes in patients with mantle cell lymphoma. Blood. 2016;127(12):1559\u201363.","journal-title":"Blood"},{"issue":"6","key":"16602_CR25","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"Wang ML, et al. Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med. 2013;369(6):507\u201316.","journal-title":"N Engl J Med"},{"issue":"3","key":"16602_CR26","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/s41375-020-01013-3","volume":"35","author":"C Visco","year":"2021","unstructured":"Visco C, et al. Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study. Leukemia. 2021;35(3):787\u201395.","journal-title":"Leukemia"},{"issue":"5","key":"16602_CR27","doi-asserted-by":"publisher","first-page":"e712","DOI":"10.1097\/HS9.0000000000000712","volume":"6","author":"M Dreyling","year":"2022","unstructured":"Dreyling M, et al. Long-term Outcomes With Ibrutinib Treatment for Patients With Relapsed\/Refractory Mantle Cell Lymphoma: A Pooled Analysis of 3 Clinical Trials With Nearly 10 Years of Follow-up. Hemasphere. 2022;6(5):e712.","journal-title":"Hemasphere"},{"issue":"14","key":"16602_CR28","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang M, et al. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med. 2020;382(14):1331\u201342.","journal-title":"N Engl J Med"},{"issue":"1","key":"16602_CR29","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke FL, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol. 2019;20(1):31\u201342.","journal-title":"Lancet Oncol"},{"issue":"26","key":"16602_CR30","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017;377(26):2531\u201344.","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"16602_CR31","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1182\/blood-2024-198021","volume":"144","author":"T van Meerten","year":"2024","unstructured":"van Meerten T, et al. Primary Analysis of ZUMA-2 Cohort 3: Brexucabtagene Autoleucel (Brexu-Cel) in Patients (Pts) with Relapsed\/Refractory Mantle Cell Lymphoma (R\/R MCL) Who Were Naive to Bruton Tyrosine Kinase Inhibitors (BTKi). Blood. 2024;144(Supplement 1):748\u2013748.","journal-title":"Blood"},{"issue":"4","key":"16602_CR32","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1111\/bjh.18519","volume":"202","author":"G Hess","year":"2023","unstructured":"Hess G, et al. Real-world experience among patients with relapsed\/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study. Br J Haematol. 2023;202(4):749\u201359.","journal-title":"Br J Haematol"},{"issue":"S2","key":"16602_CR33","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1002\/hon.111_2630","volume":"37","author":"M Wang","year":"2019","unstructured":"Wang M, et al. Safety and preliminary efficacy in patients with relapsed\/refractory mantle cell lymphoma receiving lisocabtagene maraleucel in transcend NHL 001. Hematol Oncol. 2019;37(S2):301\u20133.","journal-title":"Hematol Oncol"},{"issue":"8","key":"16602_CR34","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1182\/blood.2023021306","volume":"143","author":"A Minson","year":"2024","unstructured":"Minson A, et al. CAR T cells and time-limited ibrutinib as treatment for relapsed\/refractory mantle cell lymphoma: the phase 2 TARMAC study. Blood. 2024;143(8):673\u201384.","journal-title":"Blood"},{"issue":"19","key":"16602_CR35","doi-asserted-by":"publisher","first-page":"4653","DOI":"10.1182\/bloodadvances.2020001797","volume":"4","author":"RK Das","year":"2020","unstructured":"Das RK, et al. Lingering effects of chemotherapy on mature T cells impair proliferation. Blood Adv. 2020;4(19):4653\u201364.","journal-title":"Blood Adv"},{"issue":"8","key":"16602_CR36","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1172\/JCI89756","volume":"127","author":"M Long","year":"2017","unstructured":"Long M, et al. Ibrutinib treatment improves T cell number and function in CLL patients. J Clin Invest. 2017;127(8):3052\u201364.","journal-title":"J Clin Invest"},{"issue":"2","key":"16602_CR37","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/ijc.33212","volume":"148","author":"F Fan","year":"2021","unstructured":"Fan F, et al. Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients. Int J Cancer. 2021;148(2):419\u201328.","journal-title":"Int J Cancer"},{"issue":"7","key":"16602_CR38","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1111\/cas.14915","volume":"112","author":"M Liu","year":"2021","unstructured":"Liu M, et al. Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refractory non-Hodgkin lymphoma. Cancer Sci. 2021;112(7):2642\u201351.","journal-title":"Cancer Sci"},{"issue":"Supplement 1","key":"16602_CR39","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1182\/blood-2022-158656","volume":"140","author":"J Ruan","year":"2022","unstructured":"Ruan J, et al. Phase 2 Trial of Acalabrutinib-Lenalidomide-Rituximab (ALR) with Real-Time Monitoring of MRD in Patients with Treatment-Na\u00efve Mantle Cell Lymphoma. Blood. 2022;140(Supplement 1):175\u20137.","journal-title":"Blood"},{"key":"16602_CR40","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1182\/blood-2023-180069","volume":"142","author":"A Kumar","year":"2023","unstructured":"Kumar A, et al. A Multicenter Phase 2 Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Patients with Treatment-Na\u00efve, TP53-Mutant Mantle Cell Lymphoma. Blood. 2023;142:738.","journal-title":"Blood"},{"issue":"16","key":"16602_CR41","doi-asserted-by":"publisher","first-page":"4518","DOI":"10.1182\/bloodadvances.2023009992","volume":"7","author":"TJ Phillips","year":"2023","unstructured":"Phillips TJ, et al. Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma. Blood Adv. 2023;7(16):4518\u201327.","journal-title":"Blood Adv"},{"key":"16602_CR42","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.critrevonc.2019.02.001","volume":"136","author":"S Paydas","year":"2019","unstructured":"Paydas S. Management of adverse effects\/toxicity of ibrutinib. Crit Rev Oncol Hematol. 2019;136:56\u201363.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"16602_CR43","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transpl. 2019;25(4):625\u201338.","journal-title":"Biol Blood Marrow Transpl"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16602-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16602-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16602-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T10:33:33Z","timestamp":1786444413000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16602-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16602"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16602-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,11]]},"assertion":[{"value":"12 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This trial is conducted in accordance with the ethical principles of the Declaration of Helsinki. All participants are informed about the study objectives, procedures, potential risks and benefits, and their rights to withdraw at any time without affecting their medical care. Written informed consent is obtained from all participants before enrollment and prior to the conduct of any study-related procedures.According to national regulations, the study was approved by the competent authority Federal Institute for Drugs and Medical Devices (BfArM) and received a favorable opinion of the appropriate Ethic\u2019s Committees. The trials is conducted in accordance with Good Clinical Practice guidelines, the German Medicines Act (AMG) and after transition in accordance with EU Regulation 536\/2014. The trial is registered on EU Clinical Trial Register: 2022-502405-15-01 for Part I and Part II, submission date 21.06.2023 (ID 9283); substantial modification for Part 1 and Part II submitted on 12.08.2025 (ID 56503).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"964"}}